ClinicalTrials.govpublic full text
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above
respiratory syncytial virus infections, rsv, respiratory syncytial virus, covid-19 mrna vaccine, immunogenicity, safety, reactogenicity, older adults, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 1008766
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.